Sera Prognostics Inc (SERA)
Featured in
High-Beta Stocks
Sera Prognostics, Inc. is a healthcare company focused on women’s health. It develops and commercializes blood-based biomarker tests and related predictive analytics products and services in the United States. Its main product is the PreTRM test, a non-invasive blood test used during weeks 18 to 20 of pregnancy for women carrying a single fetus. The company also has a development pipeline that includes tests and analytics for pregnancy-related conditions such as time-to-birth, preeclampsia, and fetal growth restriction. Sera Prognostics was incorporated in 2008 and is based in Salt Lake City, Utah.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SERA
|
$2.39
|
8.5% Upside
|
Fair
|
$5.50
|
150.0% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-2.7x
|
1.3x
|
1,504.5x
|
82.233 M
|
1.497 M
|
3.0%
|
70.1%
|
-6.1
|
—
|
85.8%
|
